ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Varmus, In Letter To Institute Pasteur, Reopens Discussion Of Test Kit Royalties

July 1, 1994

BSA, BSC Approve Concept for NCI Scholars Program

March 7, 1997

In Brief: NCAB To Hear NCOG Appeal; FDA Renege On New Toxicology Protocol, Holds Up INDs

April 24, 1981

ACS Stirs Discord By Placing Its Own Logo On A Coalition’s Petition, Then Reconsiders

February 7, 1997

Scientists, Public Citizen Urge FDA To Ban Sale Of Obesity Drug Orlistat.

June 2, 2006

NCI Programs: Institute Funds 24 DNA Microarray Centers

September 24, 1999